Seattle Genetics
09:31 :
Seattle Genetics slides 11% on drug launch worries -
BOSTON (MarketWatch) -- Shares of Seattle Genetics fell 11% to $18.09 on concerns that the U.S. launch of its new oncology drug Adcentris might be delayed because of a regulatory snag. On Thursday, an advisory panel of the U.S. ...
19:16 :
Seattle Genetics promotes Eric Dobmeier to COO -
Seattle Genetics announced Friday that Eric Dobmeier has been promoted to the newly created position of chief operating officer. Dobmeier has worked with the Bothell-based biotech for nine years, most recently as chief business ...
actualidad Seattle Genetics -